logo
  

Stock Alert: Corvus Pharma Surges 111%; Study Initiated For COVID-19 Treatment

Shares of Corvus Pharmaceuticals, Inc. (CRVS) more than doubled on Tuesday morning after the clinical stage biopharmaceutical company said it commenced a Phase 1 clinical study testing a novel treatment for COVID-19.

CRVS is currently trading at $5.80, up $3.06 or 111.68%, on the Nasdaq.

Corvus announced that it has initiated an early-state study to investigate a novel immunotherapy approach for patients with COVID-19. The study is expected to enroll up to 30 patients at several sites in the United States.

The enrollment follows the FDA's review and acceptance of the company's investigational new drug application for the COVID-19 study.

Corvus is studying an agonistic (immunostimulatory) humanized monoclonal antibody, designated as CPI-006, which has demonstrated a potential new approach to immunotherapy of infectious diseases and cancer.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Cryptocurrency Dogecoin's price jumped over 15% on Friday, but later lost some of the gains, after Tesla Inc. (TSLA) CEO Elon Musk announced that the luxury car maker will start accepting the meme cryptocurrency as payment for its merchandise. "Tesla merch buyable with Dogecoin," Musk tweeted on Friday. Dogecoin... US investment bank JPMorgan Chase & Co. reported Friday a profit for the fourth quarter that declined 14 percent from last year, hurt primarily by higher noninterest expense and lower credit reserve releases. Both adjusted earnings per share and revenues for the quarter topped analysts' expectations. Microsoft Corp. said its Board of Directors has initiated a review of the effectiveness of its workplace sexual harassment and gender discrimination policies and practices. The company has hired the law firm of Arent Fox to conduct the review mainly on sexual harassment investigations, including that of co-founder Bill Gates.
Follow RTT